Goodwin Procter LLP advised Vaccitech on the deal. Vaccitech announced the completion of its $168 million Series B, including the conversion of $43 million in convertible loan…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
